Below copied from IHUB and back home up where it's
Post# of 1460
(Total Views: 609)
Posted On: 03/10/2018 8:07:19 AM
Below copied from IHUB and back home up where it's way too cold,
Fletch
Anavex Not (Presently) For Serious Investors
“Serious investors” have at best, only the most rudimentary understanding of neuron organelles, cytological physiology, protein synthesis, or homeostatic control of intra- and extra-cellular processes. Most couldn’t begin to elaborate on any of these topics --- each involved in the unique mechanism of action of the Anavex s-1 receptor agonists.
“Serious investors,” as the several here, look only at corporate revenue data. They buy shares in the belief that they will increase in value. Presently, they are unable to see or believe shares in Anavex will increase in value. For all that they know, it clearly won’t.
Who should expect these types to take AVXL positions? They can’t understand or comprehend any of the Anavex science. Every other company attacking the major central nervous system disease targets Anavex aims at has failed, often repeatedly, after spending billions, multiple times. Serious investors know, for sure, Anavex will fail, too.
Serious investors are serious, indeed. They aren’t going to fork over funds for a position, of any size, in a start-up company like Anavex Life Sciences Corp. They have no basis whatsoever upon which to invest in AVXLs. The basis of Anavex value is too complicated for them to understand, and not at all clinically proven yet.
Really serious investors won’t be taking AVXL positions until positive clinical results emerge from one of the upcoming Anavex 2-73 trials. Serious investors don’t give a whit about any underlying science; just the substantiated recognition that share prices will increase.
When it becomes clear to the scientifically illiterate that the Anavex story is real, that the company’s drugs do, indeed, provide powerful, effective, safe therapies for a number of central nervous system diseases, that illiteracy will be, again, irrelevant. Instead, projections of future corporate revenues in the global treatment of millions with CNS diseases will prompt “serious” types to buy in.
Just a matter of time and clinical results. Till then, share prices will continue to languish.
Fletch
Anavex Not (Presently) For Serious Investors
“Serious investors” have at best, only the most rudimentary understanding of neuron organelles, cytological physiology, protein synthesis, or homeostatic control of intra- and extra-cellular processes. Most couldn’t begin to elaborate on any of these topics --- each involved in the unique mechanism of action of the Anavex s-1 receptor agonists.
“Serious investors,” as the several here, look only at corporate revenue data. They buy shares in the belief that they will increase in value. Presently, they are unable to see or believe shares in Anavex will increase in value. For all that they know, it clearly won’t.
Who should expect these types to take AVXL positions? They can’t understand or comprehend any of the Anavex science. Every other company attacking the major central nervous system disease targets Anavex aims at has failed, often repeatedly, after spending billions, multiple times. Serious investors know, for sure, Anavex will fail, too.
Serious investors are serious, indeed. They aren’t going to fork over funds for a position, of any size, in a start-up company like Anavex Life Sciences Corp. They have no basis whatsoever upon which to invest in AVXLs. The basis of Anavex value is too complicated for them to understand, and not at all clinically proven yet.
Really serious investors won’t be taking AVXL positions until positive clinical results emerge from one of the upcoming Anavex 2-73 trials. Serious investors don’t give a whit about any underlying science; just the substantiated recognition that share prices will increase.
When it becomes clear to the scientifically illiterate that the Anavex story is real, that the company’s drugs do, indeed, provide powerful, effective, safe therapies for a number of central nervous system diseases, that illiteracy will be, again, irrelevant. Instead, projections of future corporate revenues in the global treatment of millions with CNS diseases will prompt “serious” types to buy in.
Just a matter of time and clinical results. Till then, share prices will continue to languish.
(1)
(0)